BioNTech Investor Day Presentation Deck

Near-term milestones for protein therapeutics Platform Product candidate BNT311 (PD-L1×4-1BB)¹ Next-gen immunomodulators BNT311 ± pembrolizumab 1 BNT312 (CD40×4-1BB)¹ ± anti PD1 ± chemotherapy FPD, first patient dosed; NSCLC, non-small-cell lung cancer; R/R, relapsed/refractory. 1 (GEN1046 and GEN10542), partnered with Genmab; 50:50 profit/loss collaboration.. Indication Multiple advanced solid tumors PD1+ R/R NSCLC Multiple advanced solid tumors Protein therapeutics Next milestone Phase 1/2 trial: 8 expansion cohorts completed 2 cohorts enrolment ongoing, 1 cohort enrolment to be started Phase 2 ongoing (FPD, December 2021) Phase 2b trial combination expansion cohorts. enrolling BIONTECH 130

View entire presentation